Gerald P. Linette
University of Pennsylvania · 268 works · 42,222 citations · h-index 60
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- Bcl-XL and Bcl-2 repress a common pathway of cell death.
- Bcl-2 is upregulated at the CD4+ CD8+ stage during positive selection and promotes thymocyte differentiation at several control Points
- Induction of anti‐HIV neutralizing antibodies by synthetic peptides.
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation.
- Bcl-2 Gene Family and the Regulation of Programmed Cell Death
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
- Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
- Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- HIV-1-Infected T Cells Show a Selective Signaling Defect After Perturbation of CD3/Antigen Receptor